Laurent Levy, Nanobiotix CEO
July 10, 2023 02:00 AM EDTUpdated 07:42 AM
Deals

A year af­ter cost cuts, Nanobi­otix has a deal with J&J to li­cense its lead ra­dioen­hancer prod­uct

Drew Armstrong

Executive Editor

Nanobi­otix and John­son & John­son have struck a li­cens­ing deal for the French biotech’s lead prod­uct, an ex­per­i­men­tal ther­a­py de­signed to boost the ef­fi­ca­cy of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times